Hearing loss and tinnitus associated with COVID-19 vaccines:An analysis from the national pharmacovigilance database in Malaysia
作者机构：National Pharmaceutical Regulatory Agency(NPRA)Ministry of HealthMalaysia
出 版 物：《Asian Pacific Journal of Tropical Medicine》 (亚太热带医药杂志（英文版）)
年 卷 期：2023年第16卷第7期
页 面：289-295,I0002-I0004页
核心收录：
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学]
主 题：COVID-19 vaccines Hearing loss Tinnitus Adverse events following immunization
摘 要：Objective:To compare the reporting pattern of hearing loss and tinnitus across different vaccines brands used in Malaysia(BNT162b2,CoronaVac,ChAdOx1,***2-S and BBIBP-CorV).Methods:This retrospective study included all reports of hearing loss and tinnitus occurring after COVID-19 vaccination that were received in the national pharmacovigilance database,QUEST,from February 24,2021 through July 31,*** given causality consistent or indeterminate were ***:There were 21 cases of hearing loss,with overall reporting rate of 0.29 cases per million *** rate was similar across BNT162b2,CoronaVac and *** tinnitus,35 cases were reported,with the overall reporting rate of 0.49 cases per million doses,and the highest rate was reported for *** both events,most cases aged 30 to 49 *** gender disparity was *** events were mainly reported to have occurred after the primary doses,with a median time-to-onset of two *** were no statistically significant differences in the reporting patterns for both events across BNT162b2,CoronaVac and ChAdOx1 by age group,gender,race,and dose ***:Despite the low reporting rates and insufficient evidence to confirm its relationship,hearing loss and tinnitus following vaccinations should not be ignored due to its disabling potential and impact on one’s quality of *** reporting is encouraged for better signal characterization in the future.
维普期刊数据库